456 Studies Now Enrolling
A Randomized, Double-blind, Parallel group, Placebo-controlled Study to investigate the efficacy, safety, and tolerability of ML-004 in adolescents and adults with autism spectrum disorders (ASD)
The IRIS Autism Trial
| Sponsor: | Maplight Therapeutics, Inc. |
| Enrolling: | Male and Female Patients |
| Study Length: | 26 Weeks |
| Clinic Visits: | 10 |
| IRB Number: | 8471 |
| U.S. Govt. ID: | NCT05081245 |
| Contact: | Suvekcha Bhattachan: 914-997-5587 / suvekcha.bhattachan@nyspi.columbia.edu |
Additional Study Information:
This study will examine the possible benefits of an investigational drug called ML-004 in adolescents and adults diagnosed with autism spectrum disorder (ASD). We are currently recruiting adult participants (18-45 years). Participation will involve ten visits to the Center for Autism and the Developing Brain in White Plains, NY over a period of 26 weeks. This will allow the study team to assess participants' general health, perform developmental testing and provide study related medical care. You will not have to pay for any study related treatments, lab tests or assessments. You will receive $50 in reimbursements for in-clinic study visits and up to $40 in travel reimbursements.
